The dual glucagon/GLP-1 receptor agonist survodutide produced dose-dependent weight loss of up to 14.9% over 46 weeks in people with obesity, outperforming placebo by a wide margin.
14.9% weight loss at highest doseAt 4.8 mg weekly for 46 weeks, survodutide produced an average 14.9% body weight reduction — roughly five times the 2.8% seen with placebo.
What the researchers found
Survodutide produced dose-dependent weight loss across all four dose groups over 46 weeks. Mean body weight changes from baseline were: -6.2% (0.6 mg), -12.5% (2.4 mg), -13.2% (3.6 mg), -14.9% (4.8 mg), compared to -2.8% with placebo.
Adverse events occurred in 91% of survodutide recipients versus 75% of placebo recipients. Gastrointestinal side effects were the most common, affecting 75% of survodutide users compared to 42% on placebo. Despite this, all doses were considered tolerable. Of the 386 treated participants, 60.4% completed the full 46-week treatment period, with similar completion rates between survodutide (61%) and placebo (60%).
Why it matters
The obesity drug landscape has been dominated by GLP-1 receptor agonists like semaglutide, but dual agonists that also activate the glucagon receptor could offer additional weight loss by increasing the body's energy expenditure on top of appetite suppression. Survodutide's 14.9% weight loss is competitive with other leading obesity drugs and establishes dual agonism as a viable therapeutic strategy. This trial laid the groundwork for Phase 3 studies that could lead to FDA approval.
How the study worked
This was a randomized, double-blind, placebo-controlled, dose-finding Phase 2 trial conducted at 43 centers across 12 countries. Participants aged 18–75 with BMI ≥27 kg/m² and without diabetes were randomly assigned (1:1:1:1:1, stratified by sex) to receive weekly subcutaneous survodutide at 0.6, 2.4, 3.6, or 4.8 mg, or placebo for 46 weeks (20 weeks dose escalation, 26 weeks dose maintenance). The primary endpoint was percentage change in body weight from baseline to week 46. The trial was funded by Boehringer Ingelheim.
What this study cannot tell us
As a Phase 2 dose-finding trial, the study was not powered for definitive efficacy conclusions. The 40% dropout rate over 46 weeks is notable, though similar to other obesity drug trials. Gastrointestinal side effects were frequent, and long-term safety beyond 46 weeks is unknown. The study excluded people with diabetes, so efficacy and safety in diabetic obesity populations is not established. The trial was funded by the drug manufacturer (Boehringer Ingelheim).
How to read the evidence
This is a well-designed Phase 2 randomized, double-blind, placebo-controlled trial published in The Lancet Diabetes & Endocrinology. The multi-center, multi-country design and rigorous methodology provide strong evidence, though Phase 2 trials are primarily for dose-finding rather than definitive efficacy determination.
When this study was published
Published in early 2024 with trial data from 2021, this is very recent and represents the current frontier of dual-agonist peptide development for obesity. Phase 3 trials are ongoing.
The bigger picture
Survodutide is part of a rapidly evolving next generation of peptide-based obesity drugs. While semaglutide (Wegovy) targets only GLP-1, and tirzepatide (Mounjaro/Zepbound) targets GLP-1 and GIP, survodutide targets GLP-1 and glucagon — a different dual mechanism. The glucagon component is thought to boost energy expenditure and improve liver fat metabolism. Multiple pharmaceutical companies are racing to develop multi-receptor peptide agonists, and this trial positions Boehringer Ingelheim's survodutide as a serious contender in what has become one of the most competitive therapeutic markets in medicine.
Questions still open
- Will Phase 3 trials confirm the weight loss efficacy and safety profile seen in this dose-finding study?
- How does survodutide's weight loss compare head-to-head with semaglutide and tirzepatide at their approved doses?
- What are the long-term effects of chronically activating the glucagon receptor alongside GLP-1, particularly on liver function and glucose homeostasis?
Common questions
How is survodutide different from semaglutide (Wegovy/Ozempic)?
What were the main side effects of survodutide?
Read the original research
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
The lancet. Diabetes & endocrinology, 12(3), 162-173
Citation
le Roux, Carel W; Steen, Oren; Lucas, Kathryn J; Startseva, Elena; Unseld, Anna; Hennige, Anita M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.. The lancet. Diabetes & endocrinology, 12(3), 162-173. https://doi.org/10.1016/S2213-8587(23)00356-X